Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics, Inc. (NASDAQ: ATXS) generates news primarily as a clinical‑stage biopharmaceutical company focused on allergic and immunologic diseases. Company updates center on its lead investigational therapy navenibart (STAR‑0215), a monoclonal antibody inhibitor of plasma kallikrein in development for hereditary angioedema (HAE), and on STAR‑0310, an investigational OX40 antagonist in development for atopic dermatitis.
News items about Astria often highlight progress in its clinical programs. For navenibart, this includes announcements on the ALPHA‑STAR Phase 1b/2 trial results in HAE patients, the global ALPHA‑ORBIT Phase 3 randomized, double‑blind, placebo‑controlled trial, and the ORBIT‑EXPANSE long‑term extension trial where all participants receive navenibart on every‑three‑month or every‑six‑month dosing schedules. Press releases have described attack‑rate reductions, safety and tolerability findings, and patient‑reported quality‑of‑life measures, as well as enrollment milestones and trial site activations across multiple regions.
Coverage also includes early‑stage results for STAR‑0310, where Astria has reported Phase 1a data in healthy subjects, including extended half‑life, durable cytokine inhibition over 16 to 20 weeks, and the absence of antibody‑dependent cellular cytotoxicity‑related side effects in the data presented. These updates are frequently tied to scientific and medical conferences in allergy and dermatology.
In addition, Astria’s news flow features corporate and strategic developments such as the definitive merger agreement with BioCryst Pharmaceuticals, Inc., under which BioCryst has agreed to acquire Astria for a mix of cash and stock, and a license agreement with Kaken Pharmaceutical Co., Ltd. for navenibart rights in Japan. Investors following ATXS news can expect a mix of clinical trial readouts, regulatory and collaboration announcements, financial updates, and transaction‑related disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.